Physician profile
Jay H Kim
NPI 1811984123
$19,323.70
in general payments reported to CMS, 2019-2025
34 companies · $3,443 in 2025
The $3,443 reported for 2025 was more than what 80% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,281 · 2020: $1,920 · 2021: $2,491 · 2022: $2,531 · 2023: $2,044 · 2024: $2,614 · 2025: $3,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,575 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $350 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,575.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $350.00 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,334.10 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $3,729.84 | 2019-2025 | |
| Janssen Biotech, INC. | $3,057.69 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,509.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,159.80 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,091.61 | 2019-2025 | |
| Lilly USA, LLC | $667.86 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $564.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $473.94 | 2022-2025 | Saphnelo |
| Radius Health, INC. | $401.84 | 2019-2025 | Tymlos |
| Genzyme Corporation | $278.89 | 2019-2025 | |
| Napo Pharmaceuticals INC | $270.73 | 2019 | |
| Celgene Corporation | $241.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.50 | 2019-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $221.96 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $216.60 | 2023-2025 | Bimzelx, Cimzia |
| Inari Medical, INC. | $152.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $121.82 | 2025 | Zoryve |
| Aurinia Pharma U.S., INC. | $118.32 | 2024-2025 | Lupkynis |
| Sobi, INC | $72.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $61.73 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $53.54 | 2019-2021 | |
| Medexus Pharma, INC. | $52.98 | 2019-2020 | |
| Genentech USA, INC. | $48.78 | 2024-2025 | Actemra |
| Boston Scientific Corporation | $42.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $40.87 | 2019-2020 | |
| Shield Therapeutics INC | $24.00 | 2025 | |
| Astellas Pharma US INC | $22.41 | 2021 | |
| Assertio Therapeutics, INC. | $14.67 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.97 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.26 | 2019 | |
| Zyla Life Sciences, INC. | $12.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.